METSERA INC (MTSR) Stock Price, Forecast & Analysis
USA - NASDAQ:MTSR - US59267L1070 - Common Stock
MTSR Key Statistics, Chart & Performance
The current stock price of MTSR is 70.5 USD. In the past month the price increased by 33.37%.
MTSR Latest News, Press Relases and Analysis
MTSR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.82 | 414.43B | ||
| AMGN | AMGEN INC | 15.63 | 184.05B | ||
| GILD | GILEAD SCIENCES INC | 15.33 | 155.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.11 | 111.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.87 | 75.73B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 912.43 | 61.00B | ||
| INSM | INSMED INC | N/A | 42.10B | ||
| NTRA | NATERA INC | N/A | 28.10B | ||
| BIIB | BIOGEN INC | 10.06 | 24.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 21.72B | ||
| INCY | INCYTE CORP | 16.29 | 20.43B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.35 | 13.83B |
Related stock screener links
About MTSR
Company Profile
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2025-01-31. The firm uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The firm's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
Company Info
METSERA INC
3 World Trade Center, 175 Greenwich Street
New York City NEW YORK US
Employees: 74
Phone: 12127846595
METSERA INC / MTSR FAQ
What does METSERA INC do?
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2025-01-31. The firm uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The firm's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
What is the stock price of METSERA INC today?
The current stock price of MTSR is 70.5 USD. The price decreased by -0.35% in the last trading session.
What is the dividend status of METSERA INC?
MTSR does not pay a dividend.
How is the ChartMill rating for METSERA INC?
MTSR has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is METSERA INC (MTSR) stock traded?
MTSR stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of MTSR stock?
METSERA INC (MTSR) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of METSERA INC (MTSR)?
METSERA INC (MTSR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.71).
MTSR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MTSR.
MTSR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MTSR. While MTSR has a great health rating, there are worries on its profitability.
MTSR Financial Highlights
Over the last trailing twelve months MTSR reported a non-GAAP Earnings per Share(EPS) of -3.71. The EPS decreased by -342.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.41% | ||
| ROE | -78.9% | ||
| Debt/Equity | 0 |
MTSR Forecast & Estimates
8 analysts have analysed MTSR and the average price target is 54.74 USD. This implies a price decrease of -22.35% is expected in the next year compared to the current price of 70.5.